Lnhc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LNHC
LNHC has two approved drugs.
There are sixteen US patents protecting LNHC drugs.
There are ninety-three patent family members on LNHC drugs in twenty-three countries and seven supplementary protection certificates in seven countries.
Summary for Lnhc
| International Patents: | 93 |
| US Patents: | 16 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Lnhc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 8,956,658 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 9,526,738 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 9,289,442 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 10,258,564 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lnhc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lnhc | XEPI | ozenoxacin | CREAM;TOPICAL | 208945-001 | Dec 11, 2017 | 6,335,447 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Lnhc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 338029 | ⤷ Start Trial |
| Japan | 6651499 | ⤷ Start Trial |
| Australia | 2006249323 | ⤷ Start Trial |
| China | 105392472 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lnhc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2344130 | 132017000093887 | Italy | ⤷ Start Trial | PRODUCT NAME: OZENOXACIN(DUBINE); AUTHORISATION NUMBER(S) AND DATE(S): ES/H/414/01/DC, 20170519;045237017, 20170711 |
| 2344130 | 300884 | Netherlands | ⤷ Start Trial | PRODUCT NAME: OZENOXACIN; REGISTRATION NO/DATE: ES/H/414/1/DC 20170519 |
| 2344130 | 2017C/031 | Belgium | ⤷ Start Trial | PRODUCT NAME: OZENOXACINE; AUTHORISATION NUMBER AND DATE: BE509591 20170519 |
| 2344130 | 2017/038 | Ireland | ⤷ Start Trial | PRODUCT NAME: OZENOXACIN; NAT REGISTRATION NO/DATE: PA1744/003/001 20170616; FIRST REGISTRATION NO/DATE: ES/H/414/01/DC 20170519 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
